BRIEF published on 07/24/2025 at 08:13, 1 year ago OPmobility Releases 2025 Interim Results Report Euronext Paris Revenue Sustainable Mobility OPmobility Interim Results
BRIEF published on 07/24/2025 at 08:13, 1 year ago Publication du Rapport Financier Semestriel 2025 d'OPmobility Chiffre D'affaires Rapport Financier Mobilité Durable 2025 OPmobility
REGULATED PRESS RELEASE published on 07/24/2025 at 08:08, 1 year ago Availability of the 2025 Interim Results Report OPmobility SE announces availability of 2025 Interim Results Report. The report can be accessed on the company's website or requested by post Financial Performance Investor Relations Sustainable Mobility OPmobility SE 2025 Interim Results Report
REGULATED PRESS RELEASE published on 07/24/2025 at 08:08, 1 year ago Mise à disposition du Rapport Financier Semestriel 2025 OPmobility publie son rapport financier semestriel 2025 en version française et anglaise. Leader mondial de la mobilité durable, chiffre d'affaires de 11,6 milliards d'euros en 2024 Chiffre D'affaires Euronext Paris Rapport Financier Mobilité Durable OPmobility
BRIEF published on 07/24/2025 at 07:05, 1 year ago OPmobility Achieves Solid Half-Year Results Amid Industry Changes Cost Reduction Free Cash Flow Operating Margin Net Debt Economic Revenue
REGULATED PRESS RELEASE published on 07/24/2025 at 07:00, 1 year ago 2025 Half-year results - Press Release OPmobility reports solid half-year results with a significant 11% increase in operating margin driven by cost reduction measures. Free cash flow up to €165 million, and continued deleveraging Cost Reduction Free Cash Flow Half-year Results Operating Margin OPmobility
REGULATED PRESS RELEASE published on 07/24/2025 at 07:00, 1 year ago Résultats du 1er semestre 2025 - Communiqué de presse
BRIEF published on 07/09/2025 at 18:05, 1 year 1 month ago Bilan du Contrat de Liquidité d'OPmobility au 30 juin 2025 Contrat De Liquidité Transactions Kepler Cheuvreux AMF OPmobility
BRIEF published on 07/09/2025 at 18:05, 1 year 1 month ago OPmobility's Half-Year Liquidity Contract Update Liquidity Contract Kepler Cheuvreux Share Transactions OPmobility AMF Regulation
REGULATED PRESS RELEASE published on 07/09/2025 at 18:00, 1 year 1 month ago Bilan semestriel du contrat de liquidité au 30 juin 2025 Bilan semestriel du contrat de liquidité de la société OPmobility avec Kepler Cheuvreux et respect de la réglementation AMF pour la pratique de marché admise Contrat De Liquidité Kepler Cheuvreux AMF OPmobility Marché Admise
Published on 08/10/2026 at 08:00, 2 hours 9 minutes ago Galantas Gold Expands Indiana Drill Program to 12,500 Metres
Published on 08/10/2026 at 08:00, 2 hours 9 minutes ago Results of AGM and Management Update Presentation
Published on 08/07/2026 at 23:15, 2 days 10 hours ago Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 11 hours ago Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/10/2026 at 09:50, 19 minutes ago Photon Energy N.V. Bond 21/27 (ISIN: DE000A3KWKY4): Signs of a crisis are mounting. What can investors do? Invitation to video conferences (German/English)
Published on 08/10/2026 at 09:00, 1 hour 9 minutes ago Original-Research: Rosenbauer International AG (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 9 minutes ago Original-Research: Bittium Oyj (von NuWays AG): BUY
Published on 08/10/2026 at 09:00, 1 hour 9 minutes ago Synnovis milestone: 2,000 revolutionary blood tests for NHS lung and breast cancer patients
Published on 08/10/2026 at 09:22, 47 minutes ago Number of shares and voting rights - July 2026 (In French only)
Published on 08/10/2026 at 09:22, 47 minutes ago Nombre total d'actions et droits de vote - juillet 2026
Published on 08/10/2026 at 07:00, 3 hours 9 minutes ago BIOPHYTIS ANNOUNCES APPROVAL OF THE OBA CLINICAL TRIAL IN BRAZIL AND SHARES ITS OUTLOOK FOR BIO101 IN OBESITY
Published on 08/10/2026 at 07:00, 3 hours 9 minutes ago Biophytis annonce l’autorisation de l’étude clinique OBA au Brésil et partage les perspectives de BIO101 dans l’obésité
